Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.51 |
| ▸ | CDK9 | P50750 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 3/20 | 0.51 |
| ▸ | SRC | P12931 | 4/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | WEE1 | P30291 | 1/20 | 0.48 |
| ▸ | AXL | P30530 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209266 | 0.83 | BRD4 (0.72) | BRD4EGFRAURKAWEE1AXL | |
| SCHEMBL3211154 | 0.81 | AXL (0.65) | BRD4CDK2EGFRAURKAAXL | |
| SCHEMBL3516113 | 0.79 | SRC (0.54) | NTRK1CDK2CCNT1CDK9CDK1 | |
| SCHEMBL657412 | 0.79 | MAPK1 (0.62) | CDK2CDK1EGFRKITAURKA | |
| SCHEMBL3209130 | 0.79 | BRD4 (0.55) | BRD4EGFRAURKAWEE1AXL | |
| SCHEMBL13485396 | 0.78 | BRD4 (0.55) | BRD4EGFRAURKAAXLJAK2 | |
| SCHEMBL3209512 | 0.78 | JAK2 (0.51) | NTRK1BRD4CDK2CCNT1CCNE1 | |
| SCHEMBL8312148 | 0.77 | CDK1 (0.62) | CDK2CDK1SRCPDGFRBABL1 | |
| SCHEMBL3302490 | 0.77 | CDK2 (0.53) | NTRK1CDK2CCNE1CDK1AURKA | |
| SCHEMBL3197568 | 0.77 | MAPK1 (0.73) | CDK2CDK1EGFRKITAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | JAK2, JAK1, IRAK4 | NTRK1 2770/4885BRD4 2018/4885CDK2 16/4885 |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | NTRK1 2475/4885BRD4 251/4885CDK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.